New One-Year Implantable Glucose Monitor Enters Trials

The study marks the first human test of a device designed to monitor blood sugar for a year without an external transmitter.

Updated on Oct. 28, 2026 in Diabetes

Isometric editorial illustration of a sleek, cylindrical medical sensor capsule resting on a clean, flat surface. — Senseonics has launched the first clinical study of its Freedom glucose monitor, an implantable device designed to function for one year. AI Illustration. Upload story photo >

Live Poll

Would you trust a medical monitor that lacks an external device for alerts and data storage?

Senseonics has initiated the first human clinical study of the Freedom glucose monitor, a device intended to track blood sugar levels for up to one year. This new system aims to simplify glucose monitoring for people with diabetes by integrating technology directly into an implantable sensor.

Why it matters

The development seeks to eliminate the need for daily adhesive changes and the use of external, rechargeable transmitters. By streamlining the monitoring process, the design intends to improve the user experience for those managing long-term glucose levels.

Preclinical testing of the Freedom system involved 18,500 data points and achieved a 100% communication success rate. Human clinical evaluations are now underway to validate these preliminary findings.

The players

Senseonics

A medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring systems.

The details

The Freedom monitor functions by embedding a battery and Bluetooth technology directly within an implantable sensor. This design allows blood sugar data to be transmitted to a smartphone without requiring an external transmitter. Because it is an implantable device, the system requires a medical procedure for both initial insertion and future replacement.

Preclinical testing was completed in the second quarter of 2026.
The first human study of the Freedom monitor began on October 26, 2026.
A larger pivotal trial is planned for 2027.
A potential commercial launch is targeted for 2028.

Health Landscape

This clinical study represents an evolution in long-term glucose management, moving toward fully self-contained implantable sensors. It follows the established precedent of the Eversense 365, further reducing the reliance on external hardware for people managing diabetes.

As this technology remains in the early stages of human clinical trials, it is not yet available for general use. Patients interested in how implantable monitoring might eventually change their routine should discuss existing long-term monitoring options with their endocrinologist.

The takeaway

The Freedom glucose monitor aims to simplify management by removing the need for external transmitters. Those interested in the future of glucose monitoring can track updates on upcoming clinical trial milestones as they become available.